Been watching this one. Done a good bit of DD. I’m not in it yet, but might have to make a move on it.

The implication below is $OPK Covid testing play. Severely Undervalued as not everyone knows it’s part of the larger testing infrastructure behind BioReference. https://twitter.com/jimcramer/status/1295340727807946757

Bio-Reference (ergo $OPK) has the NBA contract. They are the ONLY lab inside the bubble.

They recently started pool testing saliva samples to try and speed process.

In parallel, NBA & Yale were working to validate saliva testing VS. nasal swab testing.

Yale receives FDA approval for saliva testing on Saturday.

Yale has the test, Bio-Reference (ergo $OPK) is processing the tests.

Turnaround time drops from 2 DAYS to a few HOURS.

Further refining the Yale test is going to allow testing to SCALE. Millions of tests per day. It’s the panacea.

UNLOCKS:
Can handle TSA testing at airport.
Can test entire campuses in few hours.

Massive opp. $OPK is 1st mover here.

Don’t mine the gold. Sell the shovels.

$OPK Rayaldee is already FDA approved for vitamin D deficiency for stage 3 and 4 renal disease.

Ph 2 study for use in COVID is kicking off next two weeks.

OPK indicating they expect fast track approval once study is completed in mid Sept.

And $OPK is filing for NDA on stage 5 renal patients (those on dialysis) shortly

And $PFE is filing NDA for HGH in children (partnered with OPK) in Sept which triggers $270M milestone pymt

And OPK guided $380M in q3 ($300M in Q2)

And 140M sh short vs 403M float. Death Trap.

.... and the $OPK CEO and Founder owns 400m shares. (NOT A TYPO).

-640m sh Out
-403m sh “Float”
-414m sh CEO

140m sh Short (spiked)

DEATH TRAP for Short ’s